Shares of Inari Medical, Inc. (NASDAQ:NARI - Get Free Report) reached a new 52-week high during trading on Wednesday . The company traded as high as $79.95 and last traded at $79.93, with a volume of 469145 shares. The stock had previously closed at $79.88.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the stock. BTIG Research reaffirmed a "neutral" rating on shares of Inari Medical in a research note on Wednesday, January 8th. Robert W. Baird reaffirmed a "neutral" rating and set a $80.00 price target (down from $81.00) on shares of Inari Medical in a research note on Tuesday, January 7th. William Blair reaffirmed a "market perform" rating on shares of Inari Medical in a research note on Tuesday, January 7th. Oppenheimer assumed coverage on shares of Inari Medical in a research note on Tuesday, December 17th. They set an "outperform" rating and a $75.00 price target for the company. Finally, Baird R W cut shares of Inari Medical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, January 7th. Twelve investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $68.00.
View Our Latest Report on Inari Medical
Inari Medical Stock Performance
The business's fifty day moving average is $69.07 and its two-hundred day moving average is $54.31. The company has a market cap of $4.68 billion, a P/E ratio of -59.21 and a beta of 1.02.
Insider Activity
In other news, CEO Andrew Hykes sold 3,000 shares of the business's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $55.29, for a total value of $165,870.00. Following the completion of the sale, the chief executive officer now owns 439,310 shares in the company, valued at approximately $24,289,449.90. The trade was a 0.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director William Hoffman sold 60,000 shares of the business's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $55.66, for a total transaction of $3,339,600.00. Following the completion of the sale, the director now owns 441,233 shares of the company's stock, valued at approximately $24,559,028.78. This represents a 11.97 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 323,000 shares of company stock worth $18,669,070. 10.60% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Inari Medical
Several large investors have recently modified their holdings of NARI. Vestal Point Capital LP raised its stake in shares of Inari Medical by 342.9% during the 3rd quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company's stock worth $63,922,000 after acquiring an additional 1,200,000 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Inari Medical by 63.2% during the 3rd quarter. Jennison Associates LLC now owns 1,576,641 shares of the company's stock worth $65,021,000 after acquiring an additional 610,468 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Inari Medical by 101.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 795,099 shares of the company's stock worth $32,790,000 after acquiring an additional 400,198 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new position in shares of Inari Medical during the 4th quarter worth approximately $15,139,000. Finally, Norges Bank bought a new position in shares of Inari Medical during the 4th quarter worth approximately $14,447,000. Institutional investors own 90.98% of the company's stock.
About Inari Medical
(
Get Free Report)
Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
Featured Stories
Before you consider Inari Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inari Medical wasn't on the list.
While Inari Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
